{
    "id": "1250",
    "question": "A 37-year-old woman with an HIV infection comes to the physician for a follow-up examination. Six months ago, combined antiretroviral therapy consisting of dolutegravir, tenofovir, and emtricitabine was initiated. Laboratory studies show a decrease in the CD4 count and an increase in the viral load despite ongoing treatment. The patient is switched to a new treatment regimen, including a drug that acts by preventing viral DNA synthesis without undergoing intracellular phosphorylation. Which of the following is the most likely drug?",
    "options": {
        "A": "Efavirenz",
        "B": "Ritonavir",
        "C": "Raltegravir",
        "D": "Lamivudine\n\""
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To address this question, let's break down the key points and analyze each option step by step.\\n\\nThe patient is experiencing a decrease in CD4 count and an increase in viral load despite being on a combination antiretroviral therapy (cART) consisting of dolutegravir, tenofovir, and emtricitabine. The new treatment regimen includes a drug that acts by preventing viral DNA synthesis without undergoing intracellular phosphorylation.\\n\\nThe patient is already on a combination of dolutegravir, tenofovir, and emtricitabine, which are all nucleoside reverse transcriptase inhibitors (NRTIs) that work by phosphorylating the viral DNA to prevent its replication. Therefore, the new drug should have a different mechanism of action.\\n\\nLet's examine the options:\\n\\nA. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which works by binding to the reverse transcriptase enzyme and preventing its activity, but it does undergo intracellular phosphorylation. This does not fit the description of a drug that acts by preventing viral DNA synthesis without undergoing intracellular phosphorylation.\\n\\nB. Ritonavir is a protease inhibitor (PI), which works by inhibiting the proteolytic cleavage of viral proteins, but it does not directly affect viral DNA synthesis. This also does not match the desired mechanism.\\n\\nC. Raltegravir is an integrase strand transfer inhibitor (INSTI), which works by preventing the integration of viral DNA into the host genome, thereby preventing viral replication. This matches the desired mechanism of action described in the question.\\n\\nD. Lamivudine is an NRTI, similar to the existing drugs in the patient's regimen, which would not be suitable as the new drug as it would not provide a different mechanism of action.\\n\\nBased on the analysis, the most likely drug is C. Raltegravir, which acts by preventing viral DNA synthesis without undergoing intracellular phosphorylation.\", \"answer_choice\": \"C\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 11.982513189315796
}